retatrutide phase 2 study results just delivered one of the largest weight-loss signals we've ever seen in a medication trial. In a study: • Up to 24.2% mean weight loss at 48 weeks Retatrutide vs Tirzepatide (2026): Differences

Readers should verify the current authorisation status via the MHRA and EMA medicines databases, as the regulatory position may change as Phase 3 data mature

A role for glucagon-like peptide-1 in the central regulation of feeding

Time-restricted eating (limiting food intake to an 8-12 hour window) has shown some metabolic benefits in small studies, but mechanisms are not fully established and may involve multiple hormonal pathways

Awareness of these diverse techniques allows patients to make educated choices regarding their care and work towards the best possible outcome for their weight and appearance goals

[15] [16] Readers should refer to the current NICE technology appraisal and the emc SmPC for Mounjaro for the most up-to-date access criteria, as commissioning arrangements continue to evolve

While GLP-1 medications may reduce appetite and caloric intake, they can also lead to a reduction in overall protein consumption, which is vital for muscle maintenance and growth